BLA 020521 · Ony
Infasurf Preservative Free
Calfactant · Intratracheal · Surfactant
NovelOrphanLast checked: Nov 20, 2026Latest source record: Aug 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Jul 1, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
6 Phase 3, 2 recruiting
FAERS reports
63
60 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2026.
INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. INFASURF ® is a surfactant indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates < 29 weeks gestational age at risk for RDS. (1) for the rescue treatment of preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. (1)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- INFASURF PRESERVATIVE FREE · CALFACTANT 35MG/ML · SUSPENSION, INTRATRACHEAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Calfactant" as an intervention, any sponsor and status, largest first.
- Trial of Late Surfactant for Prevention of Bronchopulmonary DysplasiaPivotal-lookingCompleted
Roberta BallardAcademic, hospital or other
NCT01022580 · 511 participants · Start Jan 2010 · Primary completion Dec 2013
Drug: Infasurf surfactant (ONY, Inc.); Sham (No Treatment) · For: Bronchopulmonary Dysplasia
Sites: Little Rock, Arkansas; Berkeley, California; Oakland, California · 21 sites in all
- Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS PatientsPivotal-lookingCompleted
ONYIndustry
NCT03058666 · 477 participants · Start Mar 29, 2017 · Primary completion Jun 1, 2018
Drug: Aerosolized Calfactant · For: Respiratory Distress Syndrome
Sites: Mobile, Alabama; Phoenix, Arizona; San Diego, California · 22 sites in all
- Calfactant for Direct Acute Respiratory Distress SyndromePivotal-lookingTerminated
Pneuma Pharmaceuticals IncorporatedAcademic, hospital or other
NCT00682500 · 332 participants · Start May 2008 · Primary completion Dec 2010
Drug: Calfactant; Room Air (placebo) · For: Respiratory Distress Syndrome, Adult
Sites: Gainesville, Florida; Orlando, Florida; Chicago, Illinois · 32 sites in all
- Non Inferiority Trial Investigating Surfactants Administered Via MISTPivotal-lookingRecruiting
Endeavor HealthAcademic, hospital or other
NCT06074380 · 262 participants (planned) · Start Jan 1, 2024 · Primary completion Dec 30, 2025
Drug: MIST surfactant · For: Respiratory Distress Syndrome
Sites: Evanston, Illinois
- Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress SyndromePivotal-lookingRecruiting
Uludag UniversityAcademic, hospital or other
NCT07350018 · 234 participants (planned) · Start Jan 20, 2026 · Primary completion Feb 20, 2027
Drug: Poractant alfa; Calfactant · For: Respiratory Distress Syndrome in Premature Infants; Respiratory Distress Syndrome (RDS); Surfactant
Sites: Bursa, Turkey (Türkiye) · 5 sites in all
Children's Hospital of PhiladelphiaAcademic, hospital or other
NCT00208039 · 89 participants · Start Sep 2004
Drug: Infasurf · For: Respiratory Distress Syndrome; Bronchopulmonary Dysplasia
- Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric OxidePivotal-lookingCompleted
Roberta BallardAcademic, hospital or other
NCT00569530 · 85 participants · Start Jan 2008 · Primary completion Dec 2012
Drug: Infasurf (ONY Inc.); Sham · For: Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction); Bronchopulmonary Dysplasia
Sites: Berkeley, California; Oakland, California; San Francisco, California · 9 sites in all
- Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.Status unknown
East Carolina UniversityAcademic, hospital or other
NCT01268215 · 45 participants (planned) · Start Jul 2010 · Primary completion Jun 2012
Drug: Infasurf; Pulmicort · For: Bronchopulmonary Dysplasia
Sites: Greenville, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- endotracheal intubation complication25
- oxygen saturation decreased13
- bradycardia6
- cardio-respiratory arrest5
- pneumothorax4
- death3
- heart rate decreased3
- neonatal hypoxia3
- obstruction3
- product quality issue3
- pulmonary haemorrhage3
- bradycardia neonatal2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2013 | 16 |
| 2014 | 4 |
| 2015 | 10 |
| 2016 | 14 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Predictors of successful treatment of respiratory distress with aerosolized calfactant.
Hojnicki M, Zapata HA, Kaluarachchi DC, et al. · J Perinatol 2023 · Clinical Trial
- Aerosolized Calfactant for Newborns With Respiratory Distress: A Randomized Trial.
Cummings JJ, Gerday E, Minton S, et al. · Pediatrics 2020 · Multicenter Study, Pragmatic Clinical Trial
- Response to aerosolized calfactant in infants with respiratory distress syndrome; a post-hoc analysis of AERO-02 trial.
Kaluarachchi DC, Zapata HA, Becker HL, et al. · J Perinatol 2023 · Randomized Controlled Trial
- Comparative effectiveness of calfactant and beractant in neonatal respiratory distress syndrome: A systemic review and meta-analysis.
Haider S, Azhar N, Zahid M, et al. · Pediatr Pulmonol 2022 · Systematic Review, Meta-Analysis
- Anti-Inflammatory Effect of Surfactant Lipid in the Vaginal Mucosa: A Pilot Study.
MacNeill C, de Guzman GS, Lupo K, et al. · J Low Genit Tract Dis 2019 · Randomized Controlled Trial
- Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery.
Pinheiro JM, Santana-Rivas Q, Pezzano C · J Perinatol 2016 · Comparative Study, Randomized Controlled Trial
Sponsor: Ony
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.